Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis

NCT03401229 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03401229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03401229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
January 15, 2018
Completion date
July 31, 2020
Enrollment
413 (actual)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

nasal polyposis